-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $15

Benzinga·12/19/2025 14:04:47
語音播報
Guggenheim analyst Yatin Suneja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $15.